ECSP22040362A - Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x - Google Patents

Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x

Info

Publication number
ECSP22040362A
ECSP22040362A ECSENADI202240362A ECDI202240362A ECSP22040362A EC SP22040362 A ECSP22040362 A EC SP22040362A EC SENADI202240362 A ECSENADI202240362 A EC SENADI202240362A EC DI202240362 A ECDI202240362 A EC DI202240362A EC SP22040362 A ECSP22040362 A EC SP22040362A
Authority
EC
Ecuador
Prior art keywords
liver
derivatives
receptor agonists
compound
formula
Prior art date
Application number
ECSENADI202240362A
Other languages
English (en)
Inventor
Jeffrey Smith
Kathryn Taylor Linkens
Fupeng Ma
Zhihong Huang
Declan Hardy
Valentina Molteni
Catherine Fooks Solovay
Alec Nathanson Flyer
Duncan Shaw
Kelly D Boss
Jon Christopher Loren
Yi Fan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22040362A publication Critical patent/ECSP22040362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan aquí compuestos y composiciones farmacéuticas útiles para el tratamiento de la disfunción de la glándula de Meibomio (MGD), que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de un compuesto de Fórmula (I) o un compuesto de Fórmula (I’), o una composición farmacéutica descripta en la presente memoria.
ECSENADI202240362A 2019-11-25 2022-05-19 Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x ECSP22040362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US202063106293P 2020-10-27 2020-10-27

Publications (1)

Publication Number Publication Date
ECSP22040362A true ECSP22040362A (es) 2022-06-30

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202240362A ECSP22040362A (es) 2019-11-25 2022-05-19 Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x

Country Status (22)

Country Link
US (2) US11427586B2 (es)
EP (1) EP4065228A1 (es)
JP (1) JP2023503320A (es)
KR (1) KR20220106778A (es)
CN (1) CN114746149A (es)
AU (1) AU2020394597B2 (es)
BR (1) BR112022009942A2 (es)
CA (1) CA3157657A1 (es)
CL (1) CL2022001323A1 (es)
CO (1) CO2022006645A2 (es)
CR (1) CR20220227A (es)
DO (1) DOP2022000107A (es)
EC (1) ECSP22040362A (es)
IL (1) IL291958A (es)
JO (1) JOP20220124A1 (es)
MX (1) MX2022006151A (es)
PE (1) PE20221785A1 (es)
PH (1) PH12022551248A1 (es)
PY (1) PY2077235A (es)
TW (1) TW202132289A (es)
UY (1) UY38964A (es)
WO (1) WO2021105857A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238305A1 (en) * 2021-05-20 2024-07-18 Novartis Ag Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR102882404B1 (ko) 2022-10-28 2025-11-06 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
EP2753608A1 (en) * 2011-09-08 2014-07-16 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
EP3893887A4 (en) 2018-12-13 2023-01-04 Eyenos, Inc. LXR AGONIST IN TOPICAL OPHTHALMIC FORMULATION FOR THE TREATMENT OF DRY EYE

Also Published As

Publication number Publication date
CO2022006645A2 (es) 2022-05-31
US20220064164A1 (en) 2022-03-03
PE20221785A1 (es) 2022-11-22
EP4065228A1 (en) 2022-10-05
AU2020394597A1 (en) 2022-06-02
AU2020394597B2 (en) 2024-03-14
US20220340573A1 (en) 2022-10-27
US11427586B2 (en) 2022-08-30
IL291958A (en) 2022-06-01
CL2022001323A1 (es) 2023-03-24
CR20220227A (es) 2022-06-15
PH12022551248A1 (en) 2023-09-11
BR112022009942A2 (pt) 2022-08-09
KR20220106778A (ko) 2022-07-29
CA3157657A1 (en) 2021-06-03
UY38964A (es) 2021-06-30
PY2077235A (es) 2022-10-31
JOP20220124A1 (ar) 2023-01-30
CN114746149A (zh) 2022-07-12
TW202132289A (zh) 2021-09-01
JP2023503320A (ja) 2023-01-27
DOP2022000107A (es) 2022-06-15
WO2021105857A1 (en) 2021-06-03
MX2022006151A (es) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2021013934A (es) Compuestos y metodos para el tratamiento de covid-19.
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PY1737795A (es) Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
AR127470A1 (es) Inhibidores de lrrk2
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
AR127431A1 (es) Compuestos novedosos
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
CL2025001109A1 (es) Compuestos derivados de pirazina-carboxamida.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
CU20130004A7 (es) Agentes terapéuticos 976
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.